Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dezima Pharma

- PMLiVE

Amgen’s Kyprolis and Blincyto on track for European approval

Double CHMP recommendation backs the myeloma and leukaemia drugs

- PMLiVE

Amgen and Allergan close on Avastin biosimilar filing

ABP 215 matches reference drug in study

- PMLiVE

Amgen granted priority review for extended use of Kyprolis

Trial data shows myeloma drug's improvement over Velcade

- PMLiVE

Amgen boosts pipeline with two deals topping $3bn

AcquiresDezima Pharma and signs collaboration with Xencor

- PMLiVE

PCSK9 inhibitors vastly over-priced, says ICER report

Cost of new Amgen and Sanofi drugs comes under fire

- PMLiVE

mRNA – message received

Assessing the growing pharma interest in modified messenger RNA

- PMLiVE

Novartis launches first biosimilar Zarxio in the US

Follows Amgen's failure to block Neupogen-version from release

- PMLiVE

Amgen and Novartis collaborate on Alzheimer’s research

Will work on the development and commercialisation of BACE inhibitors

- PMLiVE

Amgen wins FDA approval for cholesterol drug Repatha

Willgive it a quick launch in the US to catch-up with Sanofi's Praluent

- PMLiVE

Sanofi’s cholesterol drug Praluent backed for European approval

CHMPdecision puts firm on-course to catch up with Amgen's Repatha

- PMLiVE

FDA approves four new medicines across multiple areas

Sanofi/Regeneron, BMS, AbbVie and Novartis all chalk up major approvals

- PMLiVE

Amgen beats Sanofi to PCSK9 inhibitor market

EC approval for Repatha gives it a lead over Praluent

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links